The Senior Director Clinical Biomarkers, BioPharma Business Development will provide strategic,

scientific, and organizational leadership across a broad oncology diagnostics portfolio. This

executive will be responsible for defining and advancing biomarker and translational medicine

strategies across early- and late-stage BioPharma collaborations in support of Natera’s strategic

goals eg TOMR and surrogacy in collaboration with Natera’s lifecycle and clinical development

teams.

The ideal candidate will bring deep expertise in oncology drug development, biomarker

strategy, and translational research, with experience spanning Phase 1–3 studies and multiple

therapeutic modalities, including immunotherapy, targeted therapy, and antibody-drug

conjugates.

Key Responsibilities

 Lead translational medicine and clinical biomarker strategy across oncology programs

within and beyond the BioPharma BD portfolio.

 Define and oversee biomarker plans supporting late-stage development in solid tumors

within the BioPharma space (Pharma Lab Services, BD partnerships) including assay

strategy, translational endpoints, data generation, data interpretation, publication

planning, and regulatory filing support.

 Partner closely with clinical development, bioinformatics, medical affairs, regulatory,

diagnostics, and commercial teams to ensure assay development portfolio and

biomarker strategies are aligned with overall BioPharma BD needs.

 Work with external partners on their Natera-supported translational research efforts to

help them leverage Natera capabilities to optimize the value of their projects: these may

include identifying novel targets, characterizing resistance mechanisms, developing

novel predictive biomarkers and next-generation clinical tools, including blood-based

biomarkers, digital pathology, radiomics, and AI/ML-enabled approaches.

 Support development and lifecycle strategies that enable successful product

differentiation, launch readiness, reimbursement, and broader clinical adoption.

BioPharma Deliverables

 Contribute to study design and evidence-generation plans that support our BioPharma

efforts across BD, Pharma Lab Services, and internal R&D.

 Work with the RWD, AI, and bioinformatics teams to develop use cases for existing data

and build out new concepts for new data types as they are created.

 Apply translational insights to inform patient selection, development decisions, and

clinical differentiation strategies for our customers.

External Relationships & Strategic Engagement

 Establish and lead strategic collaborations with BioPharma partners, academic

institutions, cooperative groups, scientific consortia, and key opinion leaders.

 Represent the company in external scientific and clinical initiatives that shape the future

of biomarker-enabled oncology development.

 Build productive external partnerships that accelerate innovation, evidence generation,

and adoption of novel translational approaches.

External Scientific Presence

 Serve as a visible scientific leader through publications, invited presentations, advisory

participation, and broader thought leadership in oncology and precision medicine.

 Maintain strong credibility in the external scientific community, with the ability to

engage effectively with academic leaders, consortia, and industry partners.

 Contribute to the company’s scientific reputation through high-impact external

presence and publication strategy.

Preferred Qualifications

 Advanced degree in a relevant scientific discipline; PhD, MD, DVM, or equivalent

strongly preferred.

 15+ years of relevant experience in translational medicine, clinical biomarker

development, oncology drug development, or related fields.

 Significant experience in biomarker-driven clinical development and medical affairs

across early- and late-stage oncology programs.

 Demonstrated success in building external scientific relationships and representing

organizations in high-profile external settings.

 Strong record of scientific leadership, cross-functional collaboration, and strategic

execution.